



# AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
CIN: L85190PB2010PLC040162

To,

Date: 01.07.2020

Manager- Listing Department  
EMERGE PLATFORM OF NSE  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Scrip Code: AJOONI

**Subject: Statement of deviation under Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015**

Dear Sir/Madam,

We enclose herewith the Statement of Deviation under Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 as on 31<sup>st</sup> March 2020.

Kindly take the same on your record.

Thanking You,

Yours Truly,  
For, AJOONI BIOTECH LIMITED

Swati Vijan  
Company Secretary  
ACS 39179

Enclosure: Statement of deviation under Regulation 32(8) of the SEBI (LODR) Regulations, 2015



# AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)  
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com  
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com  
CIN: L85190PB2010PLC040162

To,

Date: 01.07.2020

Manager- Listing Department  
EMERGE PLATFORM OF NSE  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Scrip Code: AJOONI

**Subject: Statement of deviation(s) or Variation(s) under Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.**

Dear Sir/Madam,

Ajooni Biotech Limited has allotted 22,50,000 equity shares of face value of Rs. 10/- per equity share at an issue price of Rs.15.00/- (Inclusive of security premium of Rs. 5/-) per equity share through Preferential Allotment. The purpose and object of the issue were to meet Working Capital Requirements, good quality and other business standards.

Pursuant to Regulation 32(8) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 we hereby state that there have been no deviation(s) or Variation(s) in the utilization of entire funds raised and the above said issue has been utilized/ to be utilized for the purpose for which they were issued.

Please take the same on your record.

Thanking You,

Yours Truly,

For, AJOONI BIOTECH LIMITED

  
Swati Vijan  
Company Secretary  
ACS 39179  
